Process for the preparation of nitride complexes of transition metals
AssigneeCIS Bio International
InventorsRoberto Pasqualini, Veronique Comazzi, Emmanuel Bellande
Life of this patent
Estimating the term…
Abstract
Process for the preparation of nitride complexes of transition metals for use as radiopharmaceutical products or for the synthesis of novel pharmaceutical products. The process consists in reacting an oxygenic transition metal compound such as 99m.sub.Tc, 186.sub.Re or 188.sub.Re, with a first nitrogenous ligand such as sodium nitride or a nitrogenous compound such as S-methyl, N-methyl dithiocarbazate, and a reducing agent consisting of either tin (II) or a dithionite. The product so obtained can be used for the preparation of radiopharmaceutical products by a reaction with a second ligand such as sodium dithiocarbamate.
Claims23
Process for the preparation of a product incorpoting a nitride complex of a transition metal having a part M.tbd.N with M representing the transition metal, comprising the step of reacting a solution of an oxygen compound of the transition metal M with:
- 1.degree.) a first nitrogen ligand comprising a pharmaceutically acceptable metal or ammonium nitride, or a nitrogen compound having a ##STR40## unit, in which the N's are connected to hydrogen atoms and/or monovalent organic groups or in which one of the N's is connected to the carbon atom of a divalent organic group by means of a double bond and the other N is connected to hydrogen atoms and/or monovalent organic groups and
- .degree. ) a reducing agent comprising a pharmaceutically acceptable metal or ammonium dithionite, or tin (II) present in ionic form in the solution
- wherein said transition metal is Tc or Re.
Process for the preparation of a product incorporating a nitride complex of a transition metal having a part M.tbd.N, in which M represents the transition metal, comprising the step of reacting a solution of an oxygen compound of the transition metal M with:
- 1.degree.) a first nitrogen ligand comprising a pharmaceutically acceptable metal or ammonium nitride, or a nitrogen compound having a ##STR41## unit, in which the N's are connected to hydrogen atoms and/or to monovalent organic groups, or in which one of the N's is connected to the carbon atom of a divalent organic group by means of a double bond and the other N is connected to hydrogen atoms and/or to monovalent organic groups,
- .degree. ) a reducing agent comprising a pharmaceutically acceptable metal or ammonium dithionite, or by tin (II) present in ionic form in the solution and
- 3.degree.) a second organic ligand having a member selected from the group consisting of a nucleophilic group, a monoclonal antibody, an antibody fragment, a protein and a peptide
- wherein said transition metal is Tc or Re.
Dependencies are inferred from the claim text.